Disease Overview：Obesity（OB）
Obesity is a chronic, multifactorial metabolic disorder characterized by excessive adipose tissue accumulation that impairs health and increases risk for comorbidities including type 2 diabetes, hypertension, obstructive sleep apnea, non-alcoholic fatty liver disease, and cardiovascular disease. Diagnosis relies on BMI ≥30 kg/m², supplemented by waist circumference, body composition analysis (e.g., dual-energy X-ray absorptiometry), and endocrine evaluation to rule out secondary causes—such as Cushing’s syndrome, hypothyroidism, or hypothalamic dysfunction. Management requires a multidisciplinary approach: lifestyle intervention, pharmacotherapy (e.g., GLP-1 receptor agonists like semaglutide), endoscopic bariatric therapies (e.g., intragastric balloon, endoscopic sleeve gastroplasty), and, when indicated, metabolic surgery (e.g., laparoscopic sleeve gastrectomy or Roux-en-Y gastric bypass). Long-term follow-up with endocrinologists, dietitians, and behavioral specialists is essential to sustain weight loss and mitigate relapse.
China offers distinct advantages in obesity management: its top-tier endocrinology centers—many affiliated with national key clinical disciplines—combine deep expertise in metabolic phenotyping and precision weight-loss protocols. Hospitals deploy advanced diagnostics (e.g., MRI-based visceral fat quantification, continuous glucose monitoring) and FDA-cleared endoscopic/surgical platforms. Clinical outcomes align with international benchmarks: published cohort studies report >60% excess weight loss at one year post-surgery and significant remission rates for type 2 diabetes. Crucially, treatment costs are typically 40–60% lower than in the US or Western Europe—without compromising safety or efficacy. As your dedicated medical tourism agency, we streamline access to these resources: vetting JCI-accredited hospitals, coordinating specialist consultations, clarifying all-inclusive pricing upfront, arranging visas and accommodations, and providing bilingual case management from initial assessment through post-treatment follow-up.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Obesity (Endocrinology Department)
Non-Surgical / Conservative Management
*Eligibility*: BMI ≥24 kg/m² with comorbidities (e.g., T2DM, HTN) or BMI ≥28 kg/m² without comorbidities.
- •Lifestyle Intervention Program (3–6 months)
- 12-session structured nutrition counseling (dietitian + endocrinologist): $480 - 12-session supervised physical activity coaching: $360 - Monthly HbA1c, fasting glucose, lipid panel, liver enzymes (ALT/AST/GGT), uric acid: $180/session × 6 = $1,080 - *Total Tier 1 (Mild–Moderate)*: $2,040
- •Pharmacotherapy (6-month course, requires endocrine supervision)
- *Liraglutide 3.0 mg SC daily*: Drug + monitoring: $1,560 - *Orlistat 120 mg TID*: Generic formulation + 3-month liver/kidney function labs: $320 - *All tiers include mandatory baseline ECG, renal function, and thyroid panel*: $140
Surgical / Bariatric Interventions
*Eligibility*: BMI ≥37.5 kg/m² *or* BMI ≥32.5 kg/m² with ≥2 obesity-related comorbidities (T2DM, OSA, NAFLD, HTN); failed ≥6 months of supervised medical therapy; psychological clearance required.
- •Laparoscopic Sleeve Gastrectomy (LSG)
- Procedure (including anesthesia, OR time, 3-day hospital stay, post-op lab panel): $6,800–$8,400 - 1-year follow-up (6 endocrine visits, micronutrient panels, bone density scan): $1,380
- •Laparoscopic Roux-en-Y Gastric Bypass (RYGB)
- Procedure (including extended nutritional support planning): $9,200–$11,000 - 1-year follow-up (8 endocrine visits, comprehensive micronutrient panel ×3, DEXA scan): $1,740
Special/Complex Condition Management
- •Obesity with Severe OSA (AHI ≥30): CPAP titration + endocrine-mandated weight loss prior to surgery: $840 (device rental + titration study).
- •Obesity-Related Hypothalamic Dysfunction: MRI brain + dynamic pituitary testing (GH/ACTH/cortisol stimulation): $1,680.
- •Post-Bariatric Hypoglycemia Management: Continuous glucose monitoring + specialized endocrine dietary protocol: $1,020/year.
Quick Selection Guide
- •Age <18, BMI 28–34, no comorbidities: Tier 1 lifestyle program ($2,040) — first-line, evidence-based.
- •Age 35–55, BMI 32–37, T2DM/Hypertension: Semaglutide + lifestyle ($2,060 total) — optimal risk/benefit ratio.
- •Age 40–60, BMI ≥40 or BMI ≥35 + T2DM/OSA: LSG ($9,300–$11,000 total) — highest durability for metabolic remission.
- •BMI ≥50 or severe cardiopulmonary compromise: RYGB ($12,200–$14,000 total) — superior weight loss and comorbidity resolution in super-obese cohort.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Obesity Medical Vacation Packages
Curated transparent all-inclusive packages combining Obesity treatment with China top medical destinations:
